GHK-Cu Injection Dose: What the Evidence Actually Shows

What Is GHK-Cu and Why Does Dosing Matter?

GHK-Cu is a tripeptide (glycine-histidine-lysine) naturally complexed with copper (II) ions. It circulates at roughly 200 ng/mL in young adults and falls to approximately 80 ng/mL by age 60, a decline that correlates with slower wound repair and reduced collagen turnover. 1 Because the peptide binds copper, the delivered dose must be calibrated carefully. Too little produces negligible tissue copper elevation; too much risks copper accumulation in organs where it does not belong.

Loren Pickart, whose original 1973 paper in the Journal of Biological Chemistry first identified GHK as a plasma tripeptide with hepatic regeneration properties, observed that the peptide's biological activity was dose-dependent at concentrations between 1 nM and 10 nM in cell culture. 2 Translating nanomolar cell-culture data into human subcutaneous doses requires pharmacokinetic bridging that has not yet been formally validated in a Phase III trial, which is why clinical dose ranges remain empiric.

The distinction between mcg-range dosing and mg-range dosing is also relevant here. GHK-Cu is typically dosed in the low milligram range per injection (1 mg to 10 mg), whereas BPC-157 is typically dosed in the microgram range (200 mcg to 500 mcg). Confusing the two units is a common error in online forums and can translate into a 1,000-fold overdose if a compounder fills the wrong concentration vial.

GHK-Cu Injection Dose: Ranges Used in Research and Clinical Practice

Injectable GHK-Cu is not FDA-approved for any indication. Compounding pharmacies in the United States may prepare it under 503A or 503B frameworks, and prescribers reference published preclinical and small human studies when setting doses. 3

Research-derived dose benchmarks include the following.

Wound healing and skin models. A 2015 review by Pickart and colleagues summarized data showing that GHK-Cu applied at 1 to 10 mg per injection site in animal wound models accelerated wound contraction and increased collagen production compared with vehicle controls. 4 Human dermal fibroblast studies used concentrations equivalent to roughly 1 to 5 mg per mL in media.

Subcutaneous injection in humans. Published case series and compounding pharmacy protocols most commonly cite 1 mg to 2 mg subcutaneous daily or every other day for cosmetic and recovery indications. Some practitioners titrate to 5 mg three times weekly for systemic anti-inflammatory goals, though this range lacks controlled trial support. 5

Reconstitution math. GHK-Cu powder is typically reconstituted in bacteriostatic water. A 50 mg vial diluted into 5 mL yields a concentration of 10 mg/mL. Drawing 0.2 mL delivers a 2 mg dose. Always verify the concentration on the vial label before drawing; a 50 mg vial diluted into 2 mL yields 25 mg/mL, and the same 0.2 mL syringe would then deliver 5 mg.

Suggested starting protocol (off-label, prescriber-supervised only):

• Week 1 to 2: 1 mg subcutaneous every other day (loading tolerance check)
• Week 3 to 8: 2 mg subcutaneous three times weekly
• Week 9 to 12: 2 to 5 mg subcutaneous three times weekly, based on response
• Week 13 to 16: off-cycle (allow copper homeostasis to normalize)

Injection sites are typically the abdomen, lateral thigh, or the area closest to the target tissue (for example, periorbital injection adjacent to a scar). Rotate sites to prevent local lipodystrophy.

GHK-Cu Topical Dosing

Topical GHK-Cu does not require a prescription and appears in numerous over-the-counter cosmetic formulations. Concentration matters more than volume in topical use. 6

A 2010 review of copper peptide cosmetics published on PubMed reported that 0.1% to 1% GHK-Cu applied twice daily for 12 weeks increased dermal collagen and elastin density in small split-face studies, though sample sizes were 20 to 40 subjects. 7 Concentrations above 2% were associated with a higher incidence of contact dermatitis, particularly in individuals with sensitive skin.

Practically, a consumer buying a topical serum should look for GHK-Cu listed within the first five ingredients, with a stated concentration of at least 0.1%. Products listing "copper peptide complex" without specifying GHK-Cu by name may be using a different copper-binding peptide with different pharmacokinetics. The penetration of GHK-Cu through intact skin is limited by its molecular weight (340 Da), and formulations using liposomal encapsulation or microneedle delivery systems may improve bioavailability meaningfully. 8

How BPC-157 Dosing Compares

BPC-157 (Body Protective Compound 157) is a synthetic pentadecapeptide derived from a gastric protective protein found in human gastric juice. It is studied for tendon repair, gut healing, and neuroprotection. Dosing is in the microgram range, not the milligram range. 9

A 2021 review in the Journal of Applied Physiology summarized rodent trial data showing that BPC-157 at 10 mcg/kg administered intraperitoneally accelerated Achilles tendon healing compared with saline controls. 10 Extrapolating to a 70 kg adult gives approximately 700 mcg per dose, though human trials have not confirmed this conversion.

Typical off-label subcutaneous BPC-157 protocols in compounding medicine use 200 mcg to 500 mcg once or twice daily. The lower end (200 mcg/day) is common for systemic use; the upper end (500 mcg/day) is sometimes used locally near an injured tendon or joint. Some protocols cite a maximum of 1 to 000 mcg (1 mg) daily, but this exceeds the range supported by existing small human studies. 11

BPC-157 mcg vs mg note. If a prescription reads "BPC-157 0.5 mg," that equals 500 mcg. If it reads "BPC-157 500 mcg," that is the same dose. The confusion arises when compounding pharmacies label vials in mg and patients dose in mcg without converting. A 10 mg vial reconstituted in 2 mL gives 5 mg/mL or 5 to 000 mcg/mL. A 100 mcg dose would then be 0.02 mL, a volume too small to draw accurately in a standard 1 mL insulin syringe. Vial concentration selection must match the intended dose to allow reasonable injection volumes of 0.1 to 0.5 mL.

TB-500 Dosing

TB-500 is a synthetic analogue of thymosin beta-4 (Tβ4), a 43-amino-acid peptide that regulates actin polymerization and promotes angiogenesis, cell migration, and tissue repair. 12 It differs from GHK-Cu and BPC-157 in molecular weight (4,963 Da) and is typically dosed in the 2 mg to 5 mg range.

A 2012 paper in Annals of the New York Academy of Sciences reported that thymosin beta-4 at doses between 1 mg and 6 mg in cardiac injury models reduced infarct size and promoted endothelial cell migration. 13 Human trial data for TB-500 specifically remain sparse; most evidence comes from Tβ4 studies in cardiovascular and wound healing contexts.

Standard off-label TB-500 protocols used in compounding practices include:

• Loading phase (weeks 1 to 4): 4 mg to 8 mg subcutaneous twice weekly
• Maintenance phase (weeks 5 and beyond): 2 mg to 2.5 mg once weekly

A 2020 study examining thymosin beta-4 in 60 patients with chronic venous leg ulcers found that topical Tβ4 gel at a concentration of 0.03% reduced ulcer area by 25% after 12 weeks versus 9% in the placebo group. 14 This is the strongest controlled human data available for the Tβ4 peptide class.

Stacking GHK-Cu with BPC-157 or TB-500

Combining peptides is common in performance and recovery medicine, though no clinical trial has evaluated any two-peptide stack in a randomized design. Each peptide acts through distinct mechanisms: GHK-Cu primarily modulates gene expression through antioxidant response elements, BPC-157 acts via growth hormone receptor and nitric oxide pathways, and TB-500 works through actin sequestration and VEGF upregulation. 15 The lack of shared mechanism provides a rationale for combining them, but also means adverse interactions could arise independently.

Practitioners who do prescribe stacks typically stagger injection times: GHK-Cu in the morning, BPC-157 at night, and TB-500 twice weekly on non-consecutive days. This separation reduces the number of variables if a side effect occurs. Copper intake from diet and any copper-containing supplements should be reviewed when GHK-Cu is part of a regimen, because baseline copper status affects both therapeutic response and toxicity risk. The tolerable upper intake level for copper set by the National Institutes of Health is 10 mg/day for adults. 16

Collagen synthesis, the shared downstream effect most relevant to musculoskeletal recovery, may benefit from adequate vitamin C status, since hydroxylation of proline and lysine residues requires ascorbate as a cofactor. Concurrent vitamin C at 500 mg to 1 to 000 mg daily is sometimes recommended alongside copper peptide protocols, though this has not been studied in a trial specifically examining GHK-Cu injection plus ascorbate. 17

Safety, Side Effects, and Monitoring

GHK-Cu is generally well tolerated at doses used in cosmetic and small-scale wound-healing studies. The most common adverse effects reported in topical studies are transient redness and mild irritation at the application site, occurring in approximately 5% to 10% of subjects. 18

Injectable GHK-Cu carries additional risks:

Infection. Any subcutaneous injection bypasses skin barrier defenses. Sterile technique, including alcohol swabbing of the vial septum and injection site and use of single-use sterile needles, is non-negotiable. Cellulitis and abscess formation are documented complications of non-sterile peptide self-injection.

Copper toxicity. At doses above 10 mg/day chronically, copper accumulation can impair zinc absorption and, in genetically susceptible individuals (Wilson disease carriers), accelerate hepatic copper deposition. A serum ceruloplasmin and 24-hour urine copper measurement at baseline is reasonable for any patient prescribed injectable GHK-Cu long-term.

Unknowns from compounding. Because GHK-Cu injectable products are compounded, not FDA-manufactured, purity and sterility depend entirely on the compounding pharmacy's quality assurance program. 503B outsourcing facilities are subject to current Good Manufacturing Practice (cGMP) standards and represent a higher quality tier than 503A pharmacies for sterile injectables. 19

Pregnancy and lactation. No human data exist on GHK-Cu injection safety in pregnancy. Copper requirements increase during pregnancy, but pharmacological doses via injection have not been studied. GHK-Cu injection is contraindicated in pregnancy absent compelling clinical necessity and specialist oversight.

Routine laboratory monitoring for patients on injectable GHK-Cu could reasonably include serum copper, serum zinc, ceruloplasmin, and a comprehensive metabolic panel at baseline and every 12 weeks. This monitoring schedule mirrors what is used for patients on copper-containing intrauterine devices in the context of elevated serum copper concerns. 20

Regulatory and Quality Considerations

The FDA has not approved GHK-Cu as an injectable drug for any indication. The peptide is not on the FDA's list of bulk drug substances that may be compounded under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which means compounding pharmacies prepare it under general compounding authority, not explicit FDA approval. 21

Prescribers should verify that the compounding pharmacy they use is:

1. Accredited by the Pharmacy Compounding Accreditation Board (PCAB).
2. Able to provide a Certificate of Analysis (COA) from an independent third-party laboratory for each peptide lot.
3. Registered with the state board of pharmacy in the patient's state of residence.

Patients purchasing GHK-Cu or any peptide from online "research chemical" suppliers without a valid prescription are obtaining an unapproved drug product with no quality oversight, creating substantial safety risk. The FDA has issued multiple warning letters to suppliers marketing peptides as "research only" while clearly targeting human use. 22